↓ Skip to main content

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology

Overview of attention for article published in Scientific Reports, January 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter
7 X users

Citations

dimensions_citation
88 Dimensions

Readers on

mendeley
107 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology
Published in
Scientific Reports, January 2016
DOI 10.1038/srep18848
Pubmed ID
Authors

Yuanyuan Li, Darren B. Leneghan, Kazutoyo Miura, Daria Nikolaeva, Iona J. Brian, Matthew D. J. Dicks, Alex J. Fyfe, Sarah E. Zakutansky, Simone de Cassan, Carole A. Long, Simon J. Draper, Adrian V. S. Hill, Fergal Hill, Sumi Biswas

Abstract

Transmission-blocking vaccines (TBV) target the sexual-stages of the malaria parasite in the mosquito midgut and are widely considered to be an essential tool for malaria elimination. High-titer functional antibodies are required against target antigens to achieve effective transmission-blocking activity. We have fused Pfs25, the leading malaria TBV candidate antigen to IMX313, a molecular adjuvant and expressed it both in ChAd63 and MVA viral vectors and as a secreted protein-nanoparticle. Pfs25-IMX313 expressed from viral vectors or as a protein-nanoparticle is significantly more immunogenic and gives significantly better transmission-reducing activity than monomeric Pfs25. In addition, we demonstrate that the Pfs25-IMX313 protein-nanoparticle leads to a qualitatively improved antibody response in comparison to soluble Pfs25, as well as to significantly higher germinal centre (GC) responses. These results demonstrate that antigen multimerization using IMX313 is a very promising strategy to enhance antibody responses against Pfs25, and that Pfs25-IMX313 is a highly promising TBV candidate vaccine.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Korea, Republic of 1 <1%
Unknown 106 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 23 21%
Student > Master 19 18%
Student > Bachelor 16 15%
Researcher 10 9%
Other 4 4%
Other 16 15%
Unknown 19 18%
Readers by discipline Count As %
Agricultural and Biological Sciences 23 21%
Biochemistry, Genetics and Molecular Biology 20 19%
Medicine and Dentistry 14 13%
Immunology and Microbiology 12 11%
Engineering 6 6%
Other 10 9%
Unknown 22 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 January 2016.
All research outputs
#6,343,851
of 22,837,982 outputs
Outputs from Scientific Reports
#43,283
of 123,315 outputs
Outputs of similar age
#102,721
of 393,791 outputs
Outputs of similar age from Scientific Reports
#1,069
of 3,131 outputs
Altmetric has tracked 22,837,982 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 123,315 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 393,791 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 3,131 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.